---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Access and distribution"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Access and distribution. Topics: Expanded access: intermediate-size cohort program for tumor HI, Expanded access: company program and eligibility, Expanded access: physician request and drug supplied at no cost, Anticipated care setting at launch: National Cancer Institutes and academic medical centers, and 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/access-and-distribution"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Expanded access: intermediate-size cohort program for tumor HI

> “This expanded access program is intended to provide ersodetug, an investigational drug, to eligible participants who suffer from inadequately controlled hypoglycemia due to tumor-associated hyperinsulinism and are unable to participate in ersodetug clinical trial.”
> “Participation is open to participants who meet the eligibility criteria and for whom access to the investigational drug is deemed appropriate by the treating physician.”

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="topic-2.1.2.11-2"></a>

### Expanded access: company program and eligibility

> “Rezolute supports EAPs to help patients with serious conditions access investigational therapies like ersodetug.”
> “Our EAP is designed for patients who benefited from ersodetug during clinical trials and wish to continue treatment, or for those with severe, frequent low blood sugar due to high insulin levels who have no other options.”

Source: [Rezolute for patients page](https://rezolutebio.com/for-patients)

> “In the U.S., these requests have all been individually approved by the FDA’s Office of Cardiology, Hematology, Endocrinology and Nephrology - Division of Diabetes, Lipid Disorders, and Obesity.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.11-3"></a>

### Expanded access: physician request and drug supplied at no cost

> “Enrollment was initiated by a treating physician through a named patient request (single-patient investigational new drug application) to the country health authority and was approved by local institutional review board, if required.”
> “Rezolute, Inc. (Redwood City, CA, USA) provided ersodetug at no cost to participating institutions for use under health authority–authorized compassionate use programs.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.1.2.11-4"></a>

### Anticipated care setting at launch: National Cancer Institutes and academic medical centers

> “We believe 60% of these patients are managed at the National Cancer Institutes and academic medical centers, which will be our primary focus at launch.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

> “300 centers manage 60% of patients”
> “High penetration with a small number of treaters at National Cancer Institutes and Academic Medical Centers”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.1.2.11-5"></a>

### Anticipated reimbursement: prior authorization and J-code buy and bill

> “Expect to manage ersodetug with a prior authorization aligned to the label and a step-through diazoxide for patients with insulinoma”
> “Reimbursement via J-code (buy and bill) simplifies the approval administration burden”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.1.2.11-6"></a>

### Distribution rights in the Republic of Korea

> “whose CEO serves on the Company’s board of directors, entered into an exclusive license agreement”
> “The Handok License relates to pharmaceutical products in final dosage form containing the pharmaceutical compounds developed or to be developed by the Company, including those related to ersodetug and the PKI Portfolio.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.1.2.11-7"></a>

### Specialty pharmacy or distribution network

No evidence found.

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
